Cargando…
Comparison of plasma prolactin and CEA in monitoring patients with adenocarcinoma of colon and rectum.
Plasma prolactin (PRL) and carcinoembryonic antigen (CEA) were measured by radioimmunoassay in 74 patients with adenocarcinoma of colon and rectum. The markers were correlated with disease stage, histological grade and progression/remission of disease. The circulating preoperative median PRL and CEA...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1992
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1977975/ https://www.ncbi.nlm.nih.gov/pubmed/1419646 |
_version_ | 1782135377878843392 |
---|---|
author | Bhatavdekar, J. M. Patel, D. D. Giri, D. D. Karelia, N. H. Vora, H. H. Ghosh, N. Shah, N. G. Trivedi, S. N. Balar, D. B. |
author_facet | Bhatavdekar, J. M. Patel, D. D. Giri, D. D. Karelia, N. H. Vora, H. H. Ghosh, N. Shah, N. G. Trivedi, S. N. Balar, D. B. |
author_sort | Bhatavdekar, J. M. |
collection | PubMed |
description | Plasma prolactin (PRL) and carcinoembryonic antigen (CEA) were measured by radioimmunoassay in 74 patients with adenocarcinoma of colon and rectum. The markers were correlated with disease stage, histological grade and progression/remission of disease. The circulating preoperative median PRL and CEA levels were significantly higher in colorectal cancer patients than in their respective controls. PRL was elevated in all Dukes stages and in all histological grades of the tumour whereas the rise in CEA was more pronounced in Dukes D. Out of 74 patients, 29% (21/74) developed recurrent disease and 31% (23/74) responded to the treatment. With regard to monitoring recurrence(s), the predictive value of PRL was 94% which was significantly greater than that of CEA which was only 62%. In patients who developed liver metastases PRL remained elevated whereas CEA showed more than 100-fold increase. Therefore, we feel that CEA is a better marker for monitoring patients who developed liver metastases. From our results, we suggest that PRL can be used as a better overall marker for detecting recurrence(s) in patients with colorectal adenocarcinoma. |
format | Text |
id | pubmed-1977975 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 1992 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-19779752009-09-10 Comparison of plasma prolactin and CEA in monitoring patients with adenocarcinoma of colon and rectum. Bhatavdekar, J. M. Patel, D. D. Giri, D. D. Karelia, N. H. Vora, H. H. Ghosh, N. Shah, N. G. Trivedi, S. N. Balar, D. B. Br J Cancer Research Article Plasma prolactin (PRL) and carcinoembryonic antigen (CEA) were measured by radioimmunoassay in 74 patients with adenocarcinoma of colon and rectum. The markers were correlated with disease stage, histological grade and progression/remission of disease. The circulating preoperative median PRL and CEA levels were significantly higher in colorectal cancer patients than in their respective controls. PRL was elevated in all Dukes stages and in all histological grades of the tumour whereas the rise in CEA was more pronounced in Dukes D. Out of 74 patients, 29% (21/74) developed recurrent disease and 31% (23/74) responded to the treatment. With regard to monitoring recurrence(s), the predictive value of PRL was 94% which was significantly greater than that of CEA which was only 62%. In patients who developed liver metastases PRL remained elevated whereas CEA showed more than 100-fold increase. Therefore, we feel that CEA is a better marker for monitoring patients who developed liver metastases. From our results, we suggest that PRL can be used as a better overall marker for detecting recurrence(s) in patients with colorectal adenocarcinoma. Nature Publishing Group 1992-11 /pmc/articles/PMC1977975/ /pubmed/1419646 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Research Article Bhatavdekar, J. M. Patel, D. D. Giri, D. D. Karelia, N. H. Vora, H. H. Ghosh, N. Shah, N. G. Trivedi, S. N. Balar, D. B. Comparison of plasma prolactin and CEA in monitoring patients with adenocarcinoma of colon and rectum. |
title | Comparison of plasma prolactin and CEA in monitoring patients with adenocarcinoma of colon and rectum. |
title_full | Comparison of plasma prolactin and CEA in monitoring patients with adenocarcinoma of colon and rectum. |
title_fullStr | Comparison of plasma prolactin and CEA in monitoring patients with adenocarcinoma of colon and rectum. |
title_full_unstemmed | Comparison of plasma prolactin and CEA in monitoring patients with adenocarcinoma of colon and rectum. |
title_short | Comparison of plasma prolactin and CEA in monitoring patients with adenocarcinoma of colon and rectum. |
title_sort | comparison of plasma prolactin and cea in monitoring patients with adenocarcinoma of colon and rectum. |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1977975/ https://www.ncbi.nlm.nih.gov/pubmed/1419646 |
work_keys_str_mv | AT bhatavdekarjm comparisonofplasmaprolactinandceainmonitoringpatientswithadenocarcinomaofcolonandrectum AT pateldd comparisonofplasmaprolactinandceainmonitoringpatientswithadenocarcinomaofcolonandrectum AT giridd comparisonofplasmaprolactinandceainmonitoringpatientswithadenocarcinomaofcolonandrectum AT karelianh comparisonofplasmaprolactinandceainmonitoringpatientswithadenocarcinomaofcolonandrectum AT vorahh comparisonofplasmaprolactinandceainmonitoringpatientswithadenocarcinomaofcolonandrectum AT ghoshn comparisonofplasmaprolactinandceainmonitoringpatientswithadenocarcinomaofcolonandrectum AT shahng comparisonofplasmaprolactinandceainmonitoringpatientswithadenocarcinomaofcolonandrectum AT trivedisn comparisonofplasmaprolactinandceainmonitoringpatientswithadenocarcinomaofcolonandrectum AT balardb comparisonofplasmaprolactinandceainmonitoringpatientswithadenocarcinomaofcolonandrectum |